Those plans are now under threat. The robots, which help develop cell cultures used in stem cell therapies, are on a sprawling list of products threatened with steep U.S. tariffs amid a simmering trade stand-off between Washington and Beijing.
The company is already factoring U.S. tariffs into its plans and order pipeline for next year and has tasked its sales teams with finding new markets to make up an expected shortfall from the United States.
Beike, a domestic leader in stem cell technology with government support and long-standing ties overseas, illustrates the stakes for China Inc after Washington and Beijing kicked off trade talks on Thursday and ended Friday.
